Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Equipment & Devices.”
₹1,670 Cr revenue.
COGS 33.2%, employees 18.1%.
“domestic business should probably grow around 20 to 25%, and international international business should grow around 20 to 15%.”
“guidance is between 9% to 10%.”
“domestic business overall should grow around 25% for next year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 11.9%▼ | 12.3% |
| ROCE | 15.3%▲ | 15.3% |
| Net Margin | 18.2%▲ | 8.5% |
| EBITDA Margin | 29.9%▲ | 14.9% |
| Debt To Equity | 0.08x▼ | 0.10x |
| Rev Growth 3yr | 22.3%▲ | 15.2% |
| EPS Growth 3yr | 29.8%▲ | -17.4% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,782 Cr +6.7% | ₹1,670 Cr +21.4% | ₹1,376 Cr +23.4% | ₹1,115 Cr +20.8% | ₹923 Cr +17.4% | ₹786 Cr +14.4% | ₹687 Cr +12.5% | ₹611 Cr |
| Other Income | ₹126 Cr +41.6% | ₹89 Cr +51.7% | ₹59 Cr +62.4% | ₹36 Cr -4.5% | ₹38 Cr +105.8% | ₹18 Cr -0.3% | ₹18 Cr +1.1% | ₹18 Cr |
| Total Income | ₹1,908 Cr +8.5% | ₹1,759 Cr +22.6% | ₹1,435 Cr +24.6% | ₹1,151 Cr +19.8% | ₹961 Cr +19.4% | ₹805 Cr +14.1% | ₹706 Cr +12.2% | ₹629 Cr |
| COGS | ₹566 Cr +2.0% | ₹555 Cr +14.9% | ₹483 Cr +18.9% | ₹406 Cr +16.6% | ₹348 Cr +32.9% | ₹262 Cr +20.6% | ₹217 Cr +4.0% | ₹209 Cr |
| ₹1,442 Cr +10.0% | ₹1,312 Cr +20.0% | ₹1,093 Cr +19.3% | ₹916 Cr +19.2% | ₹768 Cr +22.3% | ₹628 Cr +7.9% | ₹582 Cr +9.7% | ₹530 Cr | |
| Profit Before Tax | ₹459 Cr +2.6% | ₹447 Cr +30.9% | ₹342 Cr +45.1% | ₹236 Cr +22.2% | ₹193 Cr +9.1% | ₹177 Cr +43.0% | ₹124 Cr +23.5% | ₹100 Cr |
| Exceptional Items | (₹7 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹1 Cr |
| ₹118 Cr +3.2% | ₹114 Cr +32.5% | ₹86 Cr +47.8% | ₹58 Cr +19.4% | ₹49 Cr +10.3% | ₹44 Cr +48.0% | ₹30 Cr -13.9% | ₹35 Cr | |
| Net Profit | ₹348 Cr +2.6% | ₹339 Cr +31.1% | ₹258 Cr +44.1% | ₹179 Cr +22.4% | ₹147 Cr +7.8% | ₹136 Cr +41.7% | ₹96 Cr +46.6% | ₹65 Cr |
| Profit (Owners) | ₹348 Cr +2.7% | ₹339 Cr +31.1% | ₹258 Cr +44.1% | ₹179 Cr +22.4% | ₹147 Cr +7.8% | ₹136 Cr +41.7% | ₹96 Cr +46.6% | ₹65 Cr |
| Minority Interest | (₹0.16 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹22 Cr ↑ Recovery | (₹1 Cr) -53.3% | (₹0.88 Cr) ↓ Decline | ₹0.41 Cr +71.3% | ₹0.24 Cr +126.7% | ₹0.10 Cr -63.4% | ₹0.29 Cr | ₹0.02 Cr |
| EPS | ₹34.31 | ₹33.41 | ₹26.91 | ₹18.69 | ₹15.28 | ₹14.17 | ₹10.86 | ₹7.41 |
| Diluted Shares | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹9 Cr |
| Profit Or Loss Of Associates | ₹6 Cr +20.7% | ₹5 Cr +105.0% | ₹3 Cr +31.1% | ₹2 Cr -21.3% | ₹2 Cr -26.1% | ₹3 Cr +54.7% | ₹2 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Poly Medicure Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulati...
Poly Medicure Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulati...
Poly Medicure Limited has informed the Exchange about Investor/Analyst Meet
Poly Medicure Limited has informed the Exchange about Investors/Analysts Meet Schedule
Poly Medicure Limited has informed the Exchange about Transcript
Poly Medicure Limited has informed that Investors Call Scheduled To Be Held On 27 May, 2026 Is Cancelled - Updates On Call
Poly Medicure Limited has informed the Exchange about Copy of Newspaper Publication for the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026
Poly Medicure Limited has informed the Exchange about Investor Presentation
Poly Medicure Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 3.50 per equity share.
Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the quarter and year ended March 31, 2026.
Poly Medicure Limited has informed the Exchange about Grant Of Stock Options- Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Intimation of Investors/Analysts Call for the Audited Financial Results for the quarter and year ended 31st March, 2026.
Poly Medicure Limited has informed the Exchange about Analyst/Investors call for 30th March, 2026
Poly Medicure Limited has informed the Exchange about Analyst/Investor Call on 20th March, 2026.
Poly Medicure Limited has informed the Exchange about Investors/Analysts Call/Meet On 19Th March, 2026